Riskpilot← Back to searchSign inGet full accessBIRK NORDIC PHARMA CONSULTING AS
ASActiveOrg 916962983Nydalsveien 28, 0484 OsloOther human health activities n.e.c. · NACE 8699Est. 20163 employeeswww.birk-npc.com
Revenue 2025
NOK 9,5M
-12% vs 2024
EBITDA margin
-13.5%
-4923% vs 2024
Equity ratio
40.7%
Financial strength
Net profit 2025
NOK -1,6M
-629% vs 2024
| Revenue | NOK 9,5M | -12% |
| EBITDA | NOK -1,3M | -4923% |
| Net profit | NOK -1,6M | -629% |
| Total assets | NOK 3,8M | -28% |
| Equity | NOK 1,6M | -51% |
| Employees | 3 | — |
Legal name
BIRK NORDIC PHARMA CONSULTING AS
Org number
916962983
Legal form
Aksjeselskap
NACE code
8699 · Other human health activities n.e.c.
Founded
13. april 2016
Share capital
NOK 40 000
Employees
3 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Company purpose
Konsulenttjenester og undervisning innenfor helsetjenester, farmasøytisk industri og medisinsk utstyr, omsetning av aksjer og eiendom og annet som naturlig faller sammen med dette.
Address
Nydalsveien 28, 0484 Oslo
Website
www.birk-npc.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 12 683 | 14 173 | 19 455 | 10 804 | 9 471 |
| Staff expenses | −1 817 | −2 151 | −2 790 | −1 455 | −2 823 |
| EBITDA | 1 921 | 533 | 2 457 | 26 | −1 277 |
| Depreciation & amort. | −0 | −0 | −172 | −172 | −172 |
| EBIT | 1 921 | 533 | 2 286 | −145 | −1 449 |
| Net financials | 26 | −174 | −622 | −130 | −86 |
| Profit before tax | 1 947 | 359 | 1 663 | −276 | −1 535 |
| Tax | 433 | 109 | 373 | −54 | 81 |
| Net profit | 1 514 | 250 | 1 290 | −221 | −1 615 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 6 788 | 6 216 | 10 169 | 5 295 | 3 838 |
| Equity | 1 860 | 2 110 | 3 400 | 3 179 | 1 564 |
| Long-term debt | 900 | 290 | 0 | 0 | 0 |
| Short-term debt | 4 029 | 3 816 | 6 769 | 2 116 | 2 275 |
| Total debt | 4 928 | 4 106 | 6 769 | 2 116 | 2 275 |
EBITDA margin
-13.5%
This company
15.8%
Market median
-185% vs market
20212025
Equity ratio
40.7%
This company
38.2%
Market median
+7% vs market
20212025
Return on equity
-103.3%
This company
18.4%
Market median
-661% vs market
20212025
Net profit margin
-17.1%
This company
8.1%
Market median
-311% vs market
20212025
Asset turnover
2.47×
This company
1.12×
Market median
+121% vs market
20212025
Debt / equity
1.45×
This company
0.62×
Market median
-134% vs market
20212025
- Annual report 2025Filed via Brønnøysundsregistrene · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
BO Chief Executive Officer | Chief Executive Officer | 2016 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2020 | |
| Chairman | 2020 | |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
D.O.G. As
BIRK NORDIC PHARMA CONSULTING AS Board members of BIRK NORDIC PHARMA CONSULTING AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Bjørn Olav Snæring Selbekk | Chief Executive Officer | 0 companies |
| Carl Magnus Wickman | Board of Directors | 0 companies |
| Kjetil Herland | Chairman | 0 companies |